AstraZeneca US president seeks to assuage concerns about vaccine-related health issues

AstraZeneca reports 79 percent efficacy in US vaccine trials

Dr. Janette Nesheiwat says the vaccine data is ‘fantastic news’ in the continued fight against COVID-19.

AstraZeneca U.S. President Ruud Dobber sought to assure the American public that the company’s COVID-19 vaccine is safe, despite concerns about links to potential blood clots raised in Europe.

Dobber noted that the company carried out a large clinical trial with over 30,000 participants, which showed “no difference in clots between the placebo arm and the vaccinated arm.”

“So that’s very reassuring,” Dobber told Fox News’ Charles Payne. “On top of that, both the European regulator and the U.K. regulator last week issued a very clear statement that they didn’t see any imbalance or difference between vaccinated people versus non-vaccinated people.”

CUBA TO VACCINATE 150,000 FRONTLINE WORKERS AS PART OF FINAL PHASE OF CLINICAL TRIAL

There were reports during trials overseas of dozens of instances where blood clots occurred after vaccination.

It was not clear that the blood clots had anything to do with the vaccine, but several countries had paused distribution. Some have since said they would resume, including Italy, Germany and France.

GET FOX BUSINESS ON THE GO BY CLICKING HERE

Dobber also said that once the vaccine is cleared for Emergency Use Authorization, AstraZeneca will be able to immediately provide 30 million doses for Americans. After one month, the company said it will be able to provide a total of 50 million doses.

From there, it is estimated that it can proceed at a rate of 15 million to 20 million doses per month, which Dobber called “very substantial.”

CLICK HERE TO READ MORE FROM FOX BUSINESS

Data from a U.S. clinicial trial released on Monday showed that the vaccine had a 79% efficacy rate in preventing symptomatic cases, and a 100% efficacy rate in preventing severe illness and death.

Dobber said he was “thrilled” about the results.

Source: Read Full Article